CHO Pharma Inc.

CHO Pharma, Inc. is a biotechnology company based in Taipei City, Taiwan, founded in 2012. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters, glycosite-specific antibody-drug conjugates (ADCs), and novel antibodies and vaccines targeting carbohydrate antigens. The company also offers CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetters or ADCs. Its pipeline includes CHO-H01 in Phase I/IIa trials for refractory non-Hodgkin lymphoma, CHO-A04 in Phase I trials for various tumors and cancer stem cells, CHO-V08 vaccines for Klebsiella pneumonia, and preclinical programs CHO-H02 for solid tumors and CHO-H03 for autoimmune inflammatory conditions.